(Q36612231)

English

Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

scientific article published on 8 August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

renal carcinoma

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

J Atzpodien

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Kirchner

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

U Rebmann

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Soder

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

U Gertenbach

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Siebels

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J Roigas

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

R Raschke

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S Salm

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

B Schwindl

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S C Müller

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S Hauser

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

C Leiber

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

E Huland

14

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Heinzer

15

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S Siemer

16

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

B Metzner

17

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Heynemann

18

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

P Fornara

19

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Reitz

20

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

8 August 2006

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

95

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

463-469

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603271

0 references

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

30 September 2017

Capecitabine in the treatment of metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

30 September 2017

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

30 September 2017

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

30 September 2017

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

30 September 2017

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

30 September 2017

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

30 September 2017

Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

20 September 2018

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

20 September 2018

Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

20 September 2018

Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

20 September 2018

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

20 September 2018

Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360667

20 September 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603271

21 January 2018

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909131

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909131

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Adminis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909131

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909131

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909131

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/16909131

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603271

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36612231&oldid=1517846906"